NMDP to Present Research Advancing Transplant Access and Cell Therapy Innovation at ASH 2025

NMDP^SM, a global nonprofit leader in cell therapy, and CIBMTR^® (Center for International Blood and Marrow Transplant Research^®), will present groundbreaking research at the 67^th American Society of Hematology (ASH) Annual Meeting from Dec. 6-9 in Orlando, Fla. The data underscore NMDP’s commitment to advancing cell therapy and improving access and outcomes for all patients.

Among the accepted abstracts is an oral presentation from the ACCESS clinical trial (NCT04904588), a cornerstone of NMDP’s Donor For All research initiative which aims to develop safe and effective approaches for using mismatched unrelated donor (MMUD) transplant. This is particularly critical for patients with diverse ancestry, many of whom don’t have a fully matched donor on the international registries. ACCESS evaluated the use of post-transplant cyclophosphamide (PTCy) to prevent graft-versus-host disease (GVHD) in patients receiving peripheral blood stem cell (PBSC) grafts from mismatched unrelated donors.

In an oral presentation, investigators will report findings from a study of 268 adult participants who received 4/8 to 7/8 HLA-mismatched PBSC grafts. Among this racially and ethnically diverse cohort, one-year overall survival exceeded 80%, with similar outcomes observed between 7/8 and <7/8 donor groups. Rates of relapse, non-relapse mortality and GVHD were similarly favorable, with low incidence of primary graft failure and chronic GVHD across conditioning regimens.

“The clinical implications of these new data demonstrate that patients with common blood cancers from varied backgrounds can achieve similarly high rates of survival, whether they receive a 7/8 or less than 7/8 donor graft,” said Antonio Jimenez Jimenez, M.D., senior author and leader of the Mismatched Allogeneic Transplant Program at Sylvester Comprehensive Cancer Center, part of the University of Miami Health System. “These data are welcome news for patients for whom traditionally finding a suitably matched donor is a challenge.”

Researchers from the multi-center MEASURE (NCT05224661) study also will present orally their investigation of 255 adult patients with acute myeloid leukemia (AML) in which they sought to understand whether whole genome sequencing represented a single, standardized diagnostic method to detect underlying mutations within AML. The MEASURE Genome Atlas is a new resource for the AML community and provides novel insights into disease biology, details evidence to support clinical testing improvements, and is a resource for future diagnostic and drug development.

Other CIBMTR presentations will include additional results from ACCESS study; a trial in progress update on the ACCELERATE trial (NCT06859424), a platform protocol for testing multiple PTCy-based regimens in MMUD); and other CIBMTR-led research exploring donor matching, long-term survivorship and immune cell function.

“Together, this body of work reinforces how innovation and data-driven research are bringing us closer than ever to ensuring every patient in need of a blood stem cell transplant can find a suitable donor,” said Steven M. Devine, M.D., chief medical officer, NMDP; executive lead, CIBMTR. “We look forward to sharing our findings with the scientific community at ASH. The ACCESS trial presentations support extending suitable MMUD match considerations to include less than 7/8 using PTCy, potentially enabling near-universal donor access.”

CIBMTR is a research collaboration between the Medical College of Wisconsin^® and NMDP.

NMDP CIBMTR presentations at ASH include:

About CIBMTR^®

CIBMTR^® (Center for International Blood and Marrow Transplant Research^®) is a nonprofit research collaboration between NMDP^SM, in Minneapolis, and the Medical College of Wisconsin (MCW), in Milwaukee. CIBMTR collaborates with the global scientific community to increase survival and enrich quality of life for patients. CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of centers, and a unique database of long-term clinical data for more than 680,000 people who have received hematopoietic cell transplantation and other cellular therapies. Learn more at cibmtr.org. It is funded by the National Cancer Institute, the National Heart, Lung and Blood Institute and the National Institute for Allergy and Infectious Disease, the Health Resources and Services Administration, the Office of Naval Research, industry sponsors, MCW, and NMDP.

About NMDP^SM

At NMDP^SM, we believe each of us holds the key to curing blood cancers and disorders. As a global nonprofit leader in cell therapy, NMDP creates essential connections between researchers and supporters to inspire action and accelerate innovation to find life-saving cures. With the help of blood stem cell donors from the world’s most diverse registry and our extensive network of transplant partners, physicians and caregivers, we’re expanding access to treatment so that every patient can receive their life-saving cell therapy. NMDP. Find cures. Save lives. Learn more at nmdp.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251104774475/en/